The oversubscribed round drew backing from Remus Capital, Plug and Play, and Innovate UK alongside notable angel investors.
"We are very excited by the research and commercial potential of the Syndi Health platform. It will help us understand how better to support the mental health needs of our people and offer them the personalised digital support they need at the earliest opportunity, which is invaluable."
Catapult Ventures led the seed round alongside Neo Kuma Ventures, Wren Capital, and o2H ventures to support the Cambridge Cognition spinout.
"By establishing Monument Therapeutics, we have created an exciting new venture to develop stratified medicine in CNS drug development that could help many patients with unmet clinical needs. It leverages Cambridge Cognition’s intellectual property and provides the potential for considerable royalty payments in the future, while the Company continues to focus on the development and commercialisation of its cutting-edge digital health technologies."